HealthScribe: Amazon’s Gamble in Clinical Documentation
Amazon Web Services launched HealthScribe, a generative AI service that can listen to physician-patient conversations and create text-based summaries or notes. It was only a matter of time before Amazon followed competitors like Microsoft to enter the AI-backed clinical documentation arena. And we kind of got the hint that HealthScribe would launch back in April, after hearing…
Read MoreNeko Health: A Unique Twist on Whole-body Scans
Health tech company Neko Health raised ~$66 million in a Series A round earlier this month to help build out its preventive healthcare solutions—which include whole-body scanning services. It seems more and more people (at least on my Twitter and LinkedIn feeds) have been chatting about whole-body scans as a form of preventive healthcare. Given risks and…
Read MoreThe Rise of Humira Biosimilars and the Adoption Challenge
AbbVie’s Humira—the most financially successful drug in history—said goodbye to two decades of U.S. market exclusivity back in January when Amgen’s Humira biosimilar, Amjevita, hit the U.S. market. Now, seven months later, several new Humira biosimilars are hitting the U.S. market. In this article, I’ll highlight how several drugmakers broke through Humira’s patent fortress, discuss the latest…
Read MoreNavigating the Digital Health Funding Landscape: Insights from H1 2023
Rock Health’s latest digital health funding report hinted that funding in 2023 is on path to be the lowest funding year since 2019. Am I shocked? Nope. This latest funding trend has been something folks in the digital health community have been expecting since the 2021 funding boom. Some have even been expecting it since 2019! In…
Read MoreCost Plus Drugs: Key Updates from H1 ‘23
Mark Cuban’s Cost Plus Drug company is moving so fast that I’m struggling to keep up. I last covered Cost Plus Drugs in January when I recapped the progress the company made in 2022. I was planning on waiting a year to do another recap, but for the sake of you and me, I need to do a mid-year…
Read MoreMedicare vs. Pharma: The Legal Fallout of the Inflation Reduction Act
Just as the ball started rolling with the implementation of drug pricing regulations under the Inflation Reduction Act of 2022, pharma and its lobbying organizations promptly jumped in, saying, “Whoa, whoa, whoa, let’s slow down a bit.” Several drugmakers and lobbying groups have filed lawsuits against CMS and HHS, arguing that the Inflation Reduction Act…
Read More